Transaction (JO:) Closure deliberate within the coming days
SOMERSET, NJ & COPENHAGEN, Denmark–(BUSINESS WIRE)–Catalent, Inc. (Catalent (NYSE:), NYSE: CTLT), a frontrunner in creating and delivering higher therapies for sufferers world wide, and Novo Holdings A/S (Novo Holdings), a world life sciences funding firm, immediately introduced that the businesses have glad all regulatory closing circumstances for his or her pending transaction. The businesses now plan to finalize the transaction within the coming days.
Immediately represents an necessary milestone in our transition to non-public possession underneath Novo Holdings, a number one life sciences funding firm, stated Alessandro Maselli, President and CEO of Catalent. As we method the closing of the transaction, I wish to thank the Catalent group for all of their laborious work and share my pleasure in regards to the brilliant way forward for our firm. With the help of Novo Holdings and entry to further assets, Catalent will likely be nicely positioned to drive innovation and enhance choices to learn the shoppers and sufferers they serve, accelerating our technique to create worth for stakeholders.
We’re happy to have taken this ultimate step, which we imagine displays the numerous advantages that the proposed transaction is predicted to convey,” stated Jonathan Levy, Senior Associate at Novo Holdings. As we method closing, we’re excited to associate and help the Catalent group of their mission to drive innovation within the healthcare system and enhance affected person outcomes.
For extra data related to the transaction, please go to transaction.catalent.com.
Advisors
Citi and JP Morgan served as monetary advisors to Catalent. Skadden, Arps, Slate, Meagher & Flom LLP acted as authorized advisor to Catalent and Jones Day acted as authorized advisor to the board of administrators of Catalent. Morgan Stanley & Co (NYSE:). LLC served as monetary advisor to Novo Holdings. Goodwin Procter LLP and Linklaters LLP acted as authorized advisors to Novo Holdings. Arnold & Porter Kaye Scholer LLP and Davis Polk & Wardwell LLP acted as authorized advisors to Novo Nordisk (NYSE:).
About Novo Holdings A/S
Novo Holdings is a holding and funding firm accountable for managing the property and wealth of the Novo Nordisk Basis. Novo Holdings’ aim is to enhance the well being of individuals and the sustainability of society and the planet by producing engaging long-term returns on the property of the Novo Nordisk Basis.
Wholly owned by the Novo Nordisk Basis, Novo Holdings is almost all shareholder of Novo Nordisk A/S and Novonesis A/S (previously Novozymes (OTC:) A/S) and manages an funding portfolio with a view to long-term efficiency. Along with managing a broad portfolio of shares, bonds, actual property, infrastructure and personal fairness property, Novo Holdings is a number one life sciences investor. By its Seed, Enterprise, Development, Asia, Planetary Well being and Principal Investments groups, Novo Holdings invests in life sciences corporations in any respect phases of improvement. On the finish of 2023, Novo Holdings had whole property of €149 billion. www.novoholdings.dk
About Catalent, Inc.
Catalent, Inc. (NYSE: CTLT), is a world chief in enabling pharmaceutical, biotechnology and shopper well being companions to optimize the event, launch and provide of merchandise all through the affected person lifecycle from everywhere in the world. With broad and deep experience in developmental sciences, supply applied sciences and multimodal manufacturing, Catalent is a most popular business associate for customized medicines, shopper well being model extensions and blockbuster medicines. Catalent helps speed up greater than 1,500 associate improvement applications and launch greater than 150 new merchandise annually. Its versatile manufacturing platforms throughout greater than 50 places worldwide present almost 70 billion doses of almost 8,000 merchandise annually. Catalent’s professional workforce of roughly 17,000 consists of greater than 3,000 scientists and technicians. Headquartered in Somerset, New Jersey, the corporate generated roughly $4.4 billion in income in its 2024 fiscal yr. For extra data, go to www.catalent.com.
Ahead-looking statements
This press launch, and any associated oral statements, might embody each historic and forward-looking statements and steering. All statements aside from statements of historic truth are, or could also be deemed to be, forward-looking statements throughout the which means of Part 27A of the Securities Act of 1933, as amended, and Part 21E of the Securities Alternate Act of 1934, as amended. These forward-looking statements typically could be recognized by means of statements that embody expressions resembling imagine, count on, anticipate, intend, estimate, plan, mission, predict, hope, forecast, seemingly, might, may, goal, will, would, or different phrases or expressions with comparable meanings. Likewise, statements that describe Catalent’s targets, plans or objectives are, or could also be, forward-looking statements. These statements are primarily based on present expectations of future occasions. If underlying assumptions show inaccurate or unknown dangers or uncertainties materialize, precise outcomes may differ materially from Catalent’s expectations, projections and steering. A few of the components that would trigger precise outcomes to vary materially from the forward-looking statements embody, however aren’t restricted to, the pending merger of Catalent with an affiliate of Novo Holdings (the Merger), the consummation of the Merger underneath the anticipated circumstances and timing, together with acquiring antitrust and different regulatory approvals and clearances, satisfying different circumstances to consummation of the Merger, potential litigation referring to the Merger which may be introduced by or towards Catalent, Novo Holdings or their associates, administrators or officers, together with the results of any associated outcomes, the chance that disruptions ensuing from the merger may hurt Catalent’s relationships, and sure restrictions through the merger that will impression Catalent’s skill to pursue engaging enterprise alternatives or strategic transactions.
These forward-looking statements converse solely as of the date of this press launch or the date on which they’re made, and Catalent doesn’t undertake and particularly disclaims any obligation to publicly disclose the outcomes of any updates or revisions. of those forward-looking statements. statements which may be made to mirror future occasions or circumstances after the date of such statements or to mirror the prevalence of anticipated or unanticipated occasions.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20241213700784/en/
Catalent
Investor:
Paul Surdez
+1 (732) 537-6325
buyers@catalent.com
Media:
Laura Hortas
+1(609) 240-7025
media@catalent.com
Novo Holdings
(International requests) Marie-Louise Jersin, Senior Communications Affiliate
(US investigations) Dora Gonzalez, public relations specialist
novoholdingsmedia@novo.dk
Supply: Catalent, Inc.
#Catalent #Novo #Holdings #Meet #Regulatory #Closing #Circumstances #Pending #Transaction #Investing.com , #Gossip247
,
